A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals

Anaerostipes caccae CLB101TM️ is a next-generation probiotic isolated from healthy humans. It was shown to be in decreased abundance in people with protein-based food sensitivities/allergies. CLB101TM️ is different from most commercially available probiotics in that it directly produces butyrate. Butyrate is a naturally occurring small molecule found in the gut of healthy individuals, and it has been shown to provide clinical benefits including strengthening the gut lining, providing immune health, and supporting a balanced microbiome. The rationale for developing CLB101TM️ is to provide a probiotic that generates butyrate in the targeted intestinal locations where it can optimally benefit cells that line the gut.

NCT Number	NCT07336615
Lead Sponsor	ClostraBio Inc.
Conditions	Gastrointestinal, Overweight , Obesity
Enrollment	85 participants
Start Date	2025-10-09
Primary Completion	2026-06-23 (estimated)
Study Completion	2026-06-23 (estimated)
Updated on ClinicalTrials.gov	2026-08-13